Flibanserin (Addyi) is now approved for treating HSDD in postmenopausal women, expanding its previous indication for premenopausal women. The FDA's priority review designation for flibanserin ...
The FDA approved niraparib with abiraterone acetate and prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer based on the AMPLITUDE trial results. The trial demonstrated ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
The combination demonstrated a disease-specific survival rate of 98.7% at 12 months and 96.0% at 36 months. This episode offers practical insights for clinicians navigating complex prostate cancer ...
The group agreed that the future of NMIBC treatment depends on biomarkers that can direct patients toward the therapy most likely to work. The group agreed that treatment selection for ...
Lin Lin, MD, highlights a phase 2 trial of neoadjuvant SAbR followed by surgery in patients with newly diagnosed renal cell carcinoma and caval tumor thrombus. DFS rate was 85.3% at 6 months (95% CI, ...
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio. In this interview, Heather Florio and Stephen J. Walker, PhD, discuss the use of aloe vera in ...
Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
Technology may save health care professionals’ time and help reduce burnout. Physicians in all specialties continue to struggle with burnout, and the burden of clinical documentation—exacerbated by ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback